Dallas, Texas (PRWEB) June 18, 2014
The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges.
According to the “Global Type 1 Diabetes Market 2014-2018” report, one of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Type 1 Diabetes Market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various type 1 diabetes management drugs, which includes insulin-based replacement products and amylin analogues.
Global Type 1 Diabetes Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Type 1 Diabetes market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The report recognizes the following companies as the key players in Global Type 1 Diabetes Market: Astrazeneca plc , Eli Lilly and Co., Novo Nordisk A/S, Sanofi-Aventis US LLC, Biodel Inc., Diamyd Medical AB, DiaVacs Inc., Generex Biotechnology Corp., Lexicon Pharmaceuticals Inc., Macrogenics Inc., MannKind Corp., Osiris Therapeutics Inc., Tolerion Inc., XOMA Corp.
Purchase Report at http://www.reportsnreports.com/purchase.aspx?name=288377.
Key Market Driver
- Increasing Global Type 1 Diabetic Population.
Key Market Challenge
- Side Effects of Current Therapies.
Key Market Trend
- Focus on Emerging Markets.
Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management.
Other New Reports by Infiniti Research:
Global Choroidal Neovascularization (CNV) Market 2014-2018: CNV is defined as a process in which new blood vessels grow in the choroid through the bruch membrane, which is the innermost layer of the choroid, and attack the sub-retinal space. Even though most causes are idiopathic, the known causes are related to degeneration, infections, choroidal tumors and/or trauma. As there is currently no medical treatment for this disease, this abnormal growth can easily lead to impairment of sight or complete loss of vision.
Global Uveitis Market 2014-2018: Analysts forecast the Global Uveitis market will grow at a CAGR of 26.46 percent over the period 2013-2018. The Global Uveitis market can be segmented into three divisions: the Americas, and the EMEA and APAC regions. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of uveitis.
Global Hypodermic Needles Market 2014-2018: The report covers the present scenario and the growth prospects of the Global Hypodermic Needles market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of non-safety and safety hypodermic needles. The revenue generated in this market can be segmented based on the following types of needle, which are classified according to the safety activation mechanism:
ReportsnReports.com is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email the details on sales at reportsandreports.com.